-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

E. Donnall Thomas Lecture and Prize

Program: General Sessions
Hematology Disease Topics & Pathways:
Biological therapies, genomics, Therapies, Biological Processes, Transfusion
Monday, December 13, 2021: 9:00 AM-10:00 AM
Hall C2-C3 (Georgia World Congress Center)

Lecture Title:
Rh and Transfusion in the Era of Genomics

Chair:
Martin S. Tallman, MD, Memorial Sloan-Kettering Cancer Center
Disclosures:
Tallman: Jazz Pharma: Membership on an entity's Board of Directors or advisory committees; Oncolyze: Membership on an entity's Board of Directors or advisory committees; Roche: Membership on an entity's Board of Directors or advisory committees; Biosight: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; Innate Pharma: Membership on an entity's Board of Directors or advisory committees; Syros: Membership on an entity's Board of Directors or advisory committees; Kura: Membership on an entity's Board of Directors or advisory committees; NYU Grand Rounds: Honoraria; Mayo Clinic: Honoraria; UC DAVIS: Honoraria; Northwell Grand Rounds: Honoraria; NYU Grand Rounds: Honoraria; Danbury Hospital Tumor Board: Honoraria; Acute Leukemia Forum: Honoraria; Miami Leukemia Symposium: Honoraria; New Orleans Cancer Symposium: Honoraria; KAHR: Membership on an entity's Board of Directors or advisory committees; Orsenix: Membership on an entity's Board of Directors or advisory committees; Daiichi-Sankyo: Membership on an entity's Board of Directors or advisory committees; Abbvie: Membership on an entity's Board of Directors or advisory committees; Amgen: Research Funding; Rafael Pharmaceuticals: Research Funding; Glycomimetics: Research Funding; Biosight: Research Funding; Orsenix: Research Funding; Abbvie: Research Funding; ASH: Honoraria; NCCN: Honoraria.
Most people are aware of their Rh blood type and know that it is important in pregnancy and blood transfusion therapy. Over the last 25 years, our understanding of the structure, function, and genetics underlying the Rh proteins has evolved and advanced considerably. These insights have come from functional complementation and transport studies, evolutionary biology (diversity), protein crystallography, genomic sequencing, and the study of the detailed serologic specificity and origin of immune Rh antibodies in patients following transfusion and pregnancy. The understanding that has resulted from these studies, along with the availability of genomic tools, now serves as the foundation for individualized transfusion treatment, especially for those patients needing chronic transfusion therapy.

It remains a mystery why some patients become immunized to foreign blood group antigens when transfused and others do not. Some of the answers lie in the comparative genotypes of the patient and the donor. This lecture will focus on the association of Rh genetic diversity with alloimmunization, the use of genomic blood group antigen profiling for selection of units for transfusion, and the paradigm shift in transfusion therapy that has begun for select patients and will continue to expand for all patients as genomic data become commonplace in medicine.

Connie M. Westhoff, PhD

New York Blood Center, New York, NY

See more of: General Sessions